drugset
drugset / Trial / NCT06633419

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

NCT06633419 ↗

Phase 1 Completed 14 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelBasic science

Summary

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called carbamazepine.

Timeline

Start
2024-12-18
Primary completion
2025-02-12
Completion
2025-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule 100 mg Oral
Subject Carbamazepine Small molecule 200 mg Oral
Subject Carbamazepine Small molecule 300 mg Oral
Subject Opevesostat Small molecule — Oral
Background Fludrocortisone Other / unclassified 0.05 mg Oral
Background Fludrocortisone Other / unclassified 0.1 mg Oral
Background Prednisone Other / unclassified 5 mg Oral
Background Prednisone Other / unclassified 10 mg Oral

Indications

No indication recorded.